Other News To Note
Tuesday, April 12, 2011
RegeneRx Biopharmaceuticals Inc., of Rockville, Md., said researchers found that a fragment of Tbeta4 has the ability to inhibit a type of liver cell responsible for fibrosis and scar formation by blocking the binding of AKT to actin. Those data make possible the development of a therapeutic that can specifically identify and target cells responsible for the excessive scarring seen in liver diseases such as cirrhosis, as well as potential pathologies of the lungs, kidneys and other organs.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.